Therapeutic Index in Clinical Pharmacology

Understanding Therapeutic Index

The therapeutic index is critically important in clinical pharmacology as it represents the ratio between a drug's toxic dose and its effective dose, with narrow therapeutic index drugs requiring more careful monitoring and individualized dosing to prevent serious adverse effects while maintaining efficacy, as recommended by the British Journal of Pharmacology 1, 2
For many drugs with a wide therapeutic index and minimal toxicity profile, fixed adult dosing is adequate; however, drugs with narrow therapeutic indices require more precise dosing approaches, according to the British Journal of Pharmacology 1

Drugs with narrow therapeutic indices require individualized dose optimization when they have known exposure-response/exposure-safety relationships, are dosed near maximum tolerated dose, exhibit wide between-subject variability, or are licensed for high-risk patient populations, as proposed by the British Journal of Pharmacology 3, 2

Therapeutic drug monitoring (TDM) is particularly valuable for NTI drugs, as they typically fulfill the traditional criteria: long-term therapy, significant inter-individual but limited intra-individual PK variability, narrow therapeutic index, well-defined exposure-response relationship, and availability of appropriate bio-analytical methods, according to the British Journal of Pharmacology 4
TDM can help distinguish between pharmacokinetic and pharmacodynamic factors in the occurrence of adverse effects, especially in vulnerable populations like children, elderly, and pregnant women, as noted by Dialogues in Clinical Neuroscience 5
Given the large unpredictable pharmacokinetic variability in critically ill patients, therapeutic drug monitoring is strongly recommended for antibiotics with narrow therapeutic indices, such as aminoglycosides and vancomycin, as recommended by Intensive Care Medicine 6

Traditional therapeutic drug monitoring compares patient plasma or blood drug concentrations against defined therapeutic windows to inform dose adjustments, helping reduce dose-related toxicity for numerous NTI drugs including theophylline, phenytoin, busulfan, vancomycin, tacrolimus, and methotrexate, according to the British Journal of Pharmacology 2
Target concentration intervention (TCI) uses specific drug concentration or biomarker targets rather than broad therapeutic windows, providing dose predictions that better account for between-subject variability and lead to more accurate attainment of target drug exposure, as noted by the British Journal of Pharmacology 2
Model-informed precision dosing (MIPD) combines patient characteristics with drug-specific population pharmacokinetic models to provide individualized dosing recommendations, maximizing the chance of achieving pharmacokinetic and pharmacodynamic targets, according to the British Journal of Pharmacology 3

For drugs with narrow therapeutic indices, such as digoxin and insulin, doses are typically not rounded or are rounded to the nearest one-tenth of a milliliter from the originally calculated dose to maintain safety, as recommended by Pediatrics 7
Pharmacogenetic testing in combination with TDM is particularly valuable for NTI drugs, as genetic factors can significantly impact metabolism and therapeutic response, according to Dialogues in Clinical Neuroscience 5
In antiemetic therapy, agents with lower therapeutic indices (metoclopramide, butyrophenones, phenothiazines, and cannabinoids) should be reserved for patients intolerant of or refractory to first-line agents, highlighting how therapeutic index influences treatment algorithms, as noted by Journal of Clinical Oncology 8

Modern approaches to dose individualization increasingly involve mathematical models through model-informed precision dosing (MIPD), which can simultaneously consider multiple patient factors and sources of variability, according to the British Journal of Pharmacology 9
The adoption of precision dosing techniques is being driven by industry initiatives and clinical trials, building on existing practices for drug classes with narrow therapeutic indices such as antibiotics, anti-infectives, antiepileptics, and immunosuppressants, as recommended by the British Journal of Pharmacology 9